NLS Pharmaceutics Gets Nasdaq Listing Extension
Ticker: NCEL · Form: 6-K · Filed: Jun 25, 2024 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Jun 25, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: listing-requirements, extension, nasdaq
Related Tickers: NLS
TL;DR
NLS Pharmaceutics got more time from Nasdaq to fix its stock price, avoiding immediate delisting.
AI Summary
On June 25, 2024, NLS Pharmaceutics Ltd. announced that the Nasdaq Panel has granted their request for an extension to comply with continued listing requirements. This extension provides the company with additional time to meet the minimum bid price requirement for continued listing on the Nasdaq Capital Market.
Why It Matters
This extension gives NLS Pharmaceutics more time to address its stock price issues, potentially avoiding delisting and maintaining access to capital markets.
Risk Assessment
Risk Level: medium — While the extension is positive, the company still needs to meet the listing requirements, indicating ongoing financial or market challenges.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — The company filing the report and receiving the extension.
- Nasdaq Panel (company) — The body that granted the extension.
- June 25, 2024 (date) — The date of the press release and announcement.
FAQ
What was the specific reason for NLS Pharmaceutics needing an extension to comply with Nasdaq listing requirements?
The filing implies the extension was to comply with continued listing requirements, which typically include a minimum bid price.
What is the new deadline for NLS Pharmaceutics to meet the Nasdaq listing requirements?
The filing does not specify the exact length of the extension or the new deadline.
What is the minimum bid price requirement for the Nasdaq Capital Market?
The filing does not state the specific minimum bid price requirement, but it is a common Nasdaq rule.
What are the potential consequences if NLS Pharmaceutics fails to meet the listing requirements by the extended deadline?
Failure to meet the requirements could result in the delisting of the company's securities from the Nasdaq Capital Market.
Are there any specific actions NLS Pharmaceutics plans to take to regain compliance?
The provided text does not detail specific actions NLS Pharmaceutics intends to take to regain compliance.
Filing Stats: 260 words · 1 min read · ~1 pages · Grade level 10.7 · Accepted 2024-06-25 09:28:53
Filing Documents
- ea0208451-6k_nlspharm.htm (6-K) — 16KB
- ea020845101ex99-1_nlspharm.htm (EX-99.1) — 11KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- 0001213900-24-055442.txt ( ) — 36KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: June 25, 2024 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 2